stella
beta
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma — Stella
Recruiting
Back to Multiple Myeloma trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
United States
University of California, San Francisco, San Francisco, California
View full record on ClinicalTrials.gov